Keywords: Euthymics, DOV, Mergr plan, Shire, Buys a US campus
Euthymics and DOV Pharma to proceed with merger plan, Shire buys US campus for $165 million
Article | 02 July 2010
Confirming a previous letter of intent, privately-held Euthymics Bioscience and DOV Pharmaceutical, have signed a merger agreement in connection with ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
